Mr. Paul Reid:

On the antibody tests, I might ask my colleague to comment in a moment, but we are obviously staying very close to this in terms of what is on the market and learnings from other European countries, but there has not been a significant level of success with antibody testing. We see it having a role in the future and we want to monitor how it progresses. Some of the major global players are running some pilot projects and tests to support that overall.

On the overall cost of contact testing and tracing, it is something on which we are still in dialogue with the Department of Public Expenditure and Reform. As we brought our proposals to the Government in the last couple of weeks we set out the strategy and targets that I discussed earlier. Part of that was the funding requirement for it in the coming year.